FDA Approves First Combination Therapy For Initial Use In Patients With Moderate To Severe Hypertension Part 3

AVALIDE be a fixed-dose union of the angiotensin II receptor blocker (ARB) AVAPRO and a diuretic (hydrochlorothiazide).

AVALIDE is epitomize in support of the management of hypertension.

AVALIDE may be nearly new within patients whose blood force is not satisfactorily controlled by monotherapy.

Electra Paskett, Ph.D., of Ohio State University in Columbus and colleagues seek the delegation linking smoking times of yore and colorectal cancer among nearly 147,000 participant in the Women's Health Initiative.

The resolution of AVALIDE as initial therapy for hypertension should be substructure on an judgment of to be scheduled benefits and hazard.

Important Safety Information Use In Pregnancy: When used in pregnancy during the second and third trimesters, drugs that accomplishment exactly on the renin-angiotensin association can motivation sore and even annihilation to the sprouting fetus.

Researchers identified cardiovascular disease as a self-reported what went before of acute myocardial infarction, on the surface, or coronary revascularization track.

- Because of the hydrochlorothiazide construction block, AVALIDE is contraindicated in patients subsequent to anuria or hypersensitivity to sulfonamide-derived drugs - In patients with hardback or sodium depletion (eg, patients keenly pleasure with diuretics or on dialysis), such depletion should be correct prior to bid of AVAPRO® (irbesartan) or AVALIDE® (irbesartan-hydrochlorothiazide), or a subjugate initial dose of AVAPRO (75 mg) should be used, to abstain from possible suggestive hypotension - Hypersensitivity aversion to hydrochlorothiazide may come nearly in patients with or lacking a precedent of allergy or bronchial asthma, but are more likely in patients with such a history - Thiazide diuretics own be report to cause exacerbation or activation of systemic lupus erythematosus - Lithium generally should not be given with thiazides - Thiazides should be used with advise in patients with stern renal disease and in patients with impair hepatic gush or free-thinking liver disease, since subsidiary alterations of juice and electrolyte transport into line may precipitate hepatic coma - In placebo-controlled hypertension search, near be no have an important effect difference in adverse travels (AEs) involving AVAPRO and placebo. Adverse events that occur in at tiniest 1% of patients treated with AVAPRO and at a highly developed occurrence vs placebo integral diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%) and fatigue (4% vs 3%) - Additionally, in a study of hypertensive category 2 diabetic patients with renal disease (proteinuria ≥ 900 mg/day), the reported AEs for AVAPRO were alike to those see in hypertension studies, with the release of an increased incidence of orthostatic symptom; AVAPRO compare to placebo (both consortium received adjunctive antihypertensives): shakiness (10.2% vs 6.0%), orthostatic dizziness (5.4% vs 2.7%) and orthostatic hypotension (5.4% vs 3.2%), respectively. In patients with proteinuria, television serum potassium - In placebo-controlled hypertension studies, the furthermost verified adverse experience reported with AVALIDE that occurred in ≥1% of patients and at a higher incidence vs placebo included fatigue (7% vs 3%), musculoskeletal persecute (7% vs 5%), dizziness (8% vs 4%), and nausea/vomiting (3% vs 0%). Additionally, in studies of allay and severe hypertensives where on soil AVALIDE be used as initial therapy, the type and incidence of adverse events reported for AVALIDE were in the vein of monotherapy About sanofi-aventis Sanofi-aventis, a major overall pharmaceutical company, discover, modify and distributes medical solution to restore the live of all and sundry. Sanofi-aventis is nominated in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).